Phase 4 N=105 Insulin for Hyperglycemia in Stroke Trial
Hyperglycemia · Stroke, Acute
Primary: Glycemic Control — 10.7; 10.9 mmol/L — p=0.677
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=549 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
Relapsing Multiple Sclerosis (RMS)
Primary: Annualized Relapse Rate (ARR) — 0.076; 0.188 relapses per participant-years — p=<0.0001
Phase 3 N=545 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis (RMS)
Primary: Annualized Relapse Rate (ARR) — 0.091; 0.178 relapses per participant-years — p=0.0022
N/A N=46 Feasibility of the BREATHE Asthma Intervention Trial
Asthma Chronic · Health Behavior
Primary: Asthma Control Questionnaire — 2.34 score on a scale
Phase 3 N=66 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Neurofibromatosis Type 1 · Plexiform Neurofibromas
Primary: Mean Pain Interference Mean Score Change From Baseline to 8 Weeks Between the Acceptance and Commitment Therapy Intervention Group and the Waitlist Group — 61.93; 62.87…
Phase 2 N=418 Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Rheumatoid Arthritis
Primary: Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate — 39.3; 76.3; 55.0; 73.3 percentage of participants
Phase 2 N=24 Use of UC-MSCs for COVID-19 Patients
Corona Virus Infection · ARDS · ARDS, Human
Primary: Number of Participants With Pre-Specified Infusion Associated Adverse Events — 1; 1; 1; 1 Participants
N/A N=84 The Treatment Ambassador Program: A Pilot Intervention to Increase Treatment Initiation
HIV
Primary: Number of Participants With Treatment Initiation at 3 Months After Study Enrollment — 1; 5 Participants — p=0.105
N/A N=350 Adjunctive Mood Management for Telephone-based Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Prolonged Abstinence — 36; 40 Participants
N/A N=40 Mobile Health Intervention to Identify Early Responders to Treatment in Adolescent Obesity
Adolescent Obesity
Primary: Proportion of Patients Triaged to the Low Risk Weight Management Clinics — 28 Participants
Phase 2 N=18 Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome
Phelan-McDermid Syndrome
Primary: Change in Aberrant Behavior Checklist — -7.44; -2.42; -5; -1.71 score on a scale
N/A N=48 Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Influenza · Vaccine Virus Shedding
Primary: Number of Participants Shedding Each Vaccine Virus Measured by qPCR of Nasosorption Samples — 31 participants
N/A N=468 BestFIT: a Personalized Weight Loss Program
Obesity
Primary: Weight Change — -18.4; -15.7; -8.5; -7.4 pounds — p=0.25
N/A N=270 Comparison of Different Techniques on First Attempt Success in Difficult Vascular Access Patients
Vascular Access
Primary: Number of Participants With Success in the First Attempt — 56; 71; 53 Participants
N/A N=51 Oral Pathology Asynchronous Telementoring Pilot Study
Oral Cancer
Primary: Percentage of Dental Patients Who Strongly Agreed or Agreed That the Use of an Intra-Oral Camera By Their Dentists Helped Them to Better Understand Oral Cancer Screening…